A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...

The following is a summary of “Limited Benefit of Routine Clinical Follow-Up for Relapse Detection in Diffuse Large B-Cell ...

Drug coverage for four drugs used to treat some rare diseases was announced in Fredericton on Wednesday under a $32-million ...

For patients with relapsed/refractory large B-cell lymphoma, access to lifesaving CD19-directed chimeric antigen receptor (CAR) T-cell therapy may be limited by post-infusion monitoring protocols ...

In Canada, 1 in 12 people live with a rare disease, and for most people suffering from these diseases, the cost of treatment is unaffordable ...

During a Case-Based Roundtable® event, Catherine Coombs, MD, discussed the BRUIN trial and recent NCCN updates on chronic ...

"Congratulations!" "Er, thanks — what for?" "For beating cancer!" Congratulations are certainly due but not to me. I was just ...

The announcement is part of the National Strategy for Drugs for Rare Diseases, which has committed up to $1.4 billion for ...

Barclays analyst Peter Lawson maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) today and set a price target of $31.00.

Arvinas Holding Company (ARVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jeet ...

Today, the Governments of Canada and the province of New Brunswick signed the National Strategy for Drugs for Rare Disease (DRD) agreement to invest ...